Literature DB >> 19050052

Anti-melanocortin-4 receptor autoantibodies in obesity.

Jean-Christophe Peter1, Akkiz Bekel, Anne-Catherine Lecourt, Géraldine Zipfel, Pierre Eftekhari, Maya Nesslinger, Matthias Breidert, Sylviane Muller, Laurence Kessler, Karl G Hofbauer.   

Abstract

BACKGROUND: The melanocortin-4 receptor (MC4R) is part of an important pathway regulating energy balance. Here we report the existence of autoantibodies (autoAbs) against the MC4R in sera of obese patients.
METHODS: The autoAbs were detected after screening of 216 patients' sera by using direct and inhibition ELISA with an N-terminal sequence of the MC4R. Binding to the native MC4R was evaluated by flow cytometry, and pharmacological effects were evaluated by measuring adenylyl cyclase activity.
RESULTS: Positive results in all tests were obtained in patients with overweight or obesity (prevalence, 3.6%) but not in normal weight patients. The selective binding properties of anti-MC4R autoAbs were confirmed by surface plasmon resonance and by immunoprecipitation with the native MC4R. Finally, it was demonstrated that these autoAbs increased food intake in rats after passive transfer via intracerebroventricular injection.
CONCLUSION: These observations suggest that inhibitory anti-MC4R autoAbs might contribute to the development of obesity in a small subpopulation of patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050052     DOI: 10.1210/jc.2008-1749

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Melanocortin-4-receptor autoantibodies: a new player in obesity.

Authors:  Chandra Mohan; Anil K Agarwal
Journal:  J Clin Endocrinol Metab       Date:  2009-03       Impact factor: 5.958

Review 2.  Autoantibodies as Endogenous Modulators of GPCR Signaling.

Authors:  Meredith A Skiba; Andrew C Kruse
Journal:  Trends Pharmacol Sci       Date:  2020-12-24       Impact factor: 14.819

3.  Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies.

Authors:  R Malek; A Y Chong; B C Lupsa; A O Lungu; E K Cochran; M A Soos; R K Semple; J E Balow; P Gorden
Journal:  J Clin Endocrinol Metab       Date:  2010-05-19       Impact factor: 5.958

Review 4.  Syndromic insulin resistance: models for the therapeutic basis of the metabolic syndrome and other targets of insulin resistance.

Authors:  Phillip Gorden; Elika Safar Zadeh; Elaine Cochran; Rebecca J Brown
Journal:  Endocr Pract       Date:  2012 Sep-Oct       Impact factor: 3.443

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.